Literature DB >> 21647790

Mechanism-based pharmacokinetic-pharmacodynamic modeling of the dopamine D2 receptor occupancy of olanzapine in rats.

Martin Johnson1, Magdalena Kozielska, Venkatesh Pilla Reddy, An Vermeulen, Cheryl Li, Sarah Grimwood, Rik de Greef, Geny M M Groothuis, Meindert Danhof, Johannes H Proost.   

Abstract

PURPOSE: A mechanism-based PK-PD model was developed to predict the time course of dopamine D(2) receptor occupancy (D(2)RO) in rat striatum following administration of olanzapine, an atypical antipsychotic drug.
METHODS: A population approach was utilized to quantify both the pharmacokinetics and pharmacodynamics of olanzapine in rats using the exposure (plasma and brain concentration) and D(2)RO profile obtained experimentally at various doses (0.01-40 mg/kg) administered by different routes. A two-compartment pharmacokinetic model was used to describe the plasma pharmacokinetic profile. A hybrid physiology- and mechanism-based model was developed to characterize the D(2) receptor binding in the striatum and was fitted sequentially to the data. The parameters were estimated using nonlinear mixed-effects modeling .
RESULTS: Plasma, brain concentration profiles and time course of D(2)RO were well described by the model; validity of the proposed model is supported by good agreement between estimated association and dissociation rate constants and in vitro values from literature.
CONCLUSION: This model includes both receptor binding kinetics and pharmacokinetics as the basis for the prediction of the D(2)RO in rats. Moreover, this modeling framework can be applied to scale the in vitro and preclinical information to clinical receptor occupancy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21647790      PMCID: PMC3170473          DOI: 10.1007/s11095-011-0477-7

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  38 in total

1.  Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding.

Authors:  A Schotte; P F Janssen; W Gommeren; W H Luyten; P Van Gompel; A S Lesage; K De Loore; J E Leysen
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

Review 2.  Pharmacokinetics/Pharmacodynamics and the stages of drug development: role of modeling and simulation.

Authors:  Jenny Y Chien; Stuart Friedrich; Michael A Heathman; Dinesh P de Alwis; Vikram Sinha
Journal:  AAPS J       Date:  2005-10-07       Impact factor: 4.009

3.  PsN-Toolkit--a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM.

Authors:  Lars Lindbom; Pontus Pihlgren; E Niclas Jonsson; Niclas Jonsson
Journal:  Comput Methods Programs Biomed       Date:  2005-09       Impact factor: 5.428

Review 4.  Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research.

Authors:  Meindert Danhof; Elizabeth C M de Lange; Oscar E Della Pasqua; Bart A Ploeger; Rob A Voskuyl
Journal:  Trends Pharmacol Sci       Date:  2008-03-18       Impact factor: 14.819

5.  The simultaneous estimation of the influx and efflux blood-brain barrier permeabilities of gabapentin using a microdialysis-pharmacokinetic approach.

Authors:  Y Wang; D F Welty
Journal:  Pharm Res       Date:  1996-03       Impact factor: 4.200

6.  In vitro P-glycoprotein affinity for atypical and conventional antipsychotics.

Authors:  David W Boulton; C Lindsay DeVane; Heidi L Liston; John S Markowitz
Journal:  Life Sci       Date:  2002-05-31       Impact factor: 5.037

7.  Within-subject comparison of striatal D2 receptor occupancy measurements using [123I]IBZM SPECT and [11C]Raclopride PET.

Authors:  Ana M Catafau; Marina Suarez; Santiago Bullich; Jordi Llop; Gianluca Nucci; Roger N Gunn; Claire Brittain; Marc Laruelle
Journal:  Neuroimage       Date:  2009-02-20       Impact factor: 6.556

8.  Validation of a rat in vivo [(3)H]M100907 binding assay to determine a translatable measure of 5-HT(2A) receptor occupancy.

Authors:  Christopher S Knauer; Jeffrey E Campbell; Betsy Galvan; Christopher Bowman; Sarah Osgood; Susan Buist; Lisa Buchholz; Brian Henry; Erik H F Wong; Mohammed Shahid; Sarah Grimwood
Journal:  Eur J Pharmacol       Date:  2008-06-19       Impact factor: 4.432

9.  Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds--implications for pharmacokinetics of selected substrates.

Authors:  Amal Abou El Ela; Sebastian Härtter; Ulrich Schmitt; Christoph Hiemke; Hildegard Spahn-Langguth; Peter Langguth
Journal:  J Pharm Pharmacol       Date:  2004-08       Impact factor: 3.765

Review 10.  Schizophrenia: from developmental deviance to dopamine dysregulation.

Authors:  Robin M Murray; Julia Lappin; Marta Di Forti
Journal:  Eur Neuropsychopharmacol       Date:  2008-05-21       Impact factor: 4.600

View more
  8 in total

1.  Simulation of PET scan timings for receptor occupancy studies of CNS drugs: a simple fixed-time design performed as well as scattered time point designs.

Authors:  Jongtae Lee; Sangil Jeon; Taegon Hong; Seunghoon Han; Dong-Seok Yim
Journal:  Eur J Clin Pharmacol       Date:  2015-09-09       Impact factor: 2.953

2.  Pharmacokinetic-pharmacodynamic modeling of the D₂ and 5-HT (2A) receptor occupancy of risperidone and paliperidone in rats.

Authors:  Magdalena Kozielska; Martin Johnson; Venkatesh Pilla Reddy; An Vermeulen; Cheryl Li; Sarah Grimwood; Rik de Greef; Geny M M Groothuis; Meindert Danhof; Johannes H Proost
Journal:  Pharm Res       Date:  2012-03-22       Impact factor: 4.200

3.  A systematic microdialysis study of dopamine transmission in the accumbens shell/core and prefrontal cortex after acute antipsychotics.

Authors:  Gianluigi Tanda; Valentina Valentini; Maria Antonietta De Luca; Valentina Perra; Gian Pietro Serra; Gaetano Di Chiara
Journal:  Psychopharmacology (Berl)       Date:  2014-10-28       Impact factor: 4.530

4.  Translational Modeling in Schizophrenia: Predicting Human Dopamine D2 Receptor Occupancy.

Authors:  Martin Johnson; Magdalena Kozielska; Venkatesh Pilla Reddy; An Vermeulen; Hugh A Barton; Sarah Grimwood; Rik de Greef; Geny M M Groothuis; Meindert Danhof; Johannes H Proost
Journal:  Pharm Res       Date:  2015-12-30       Impact factor: 4.200

5.  Dopamine D2 receptor occupancy as a predictor of catalepsy in rats: a pharmacokinetic-pharmacodynamic modeling approach.

Authors:  Martin Johnson; Magdalena Kozielska; Venkatesh Pilla Reddy; An Vermeulen; Hugh A Barton; Sarah Grimwood; Rik de Greef; Geny M M Groothuis; Meindert Danhof; Johannes H Proost
Journal:  Pharm Res       Date:  2014-05-03       Impact factor: 4.200

6.  Semi-mechanistic modelling of the analgesic effect of gabapentin in the formalin-induced rat model of experimental pain.

Authors:  A Taneja; I F Troconiz; M Danhof; O Della Pasqua
Journal:  Pharm Res       Date:  2013-10-05       Impact factor: 4.200

7.  Kinetics of drug action in disease states: towards physiology-based pharmacodynamic (PBPD) models.

Authors:  Meindert Danhof
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-08-30       Impact factor: 2.745

8.  Prediction of brain clozapine and norclozapine concentrations in humans from a scaled pharmacokinetic model for rat brain and plasma pharmacokinetics.

Authors:  Claire H Li; Robert E Stratford; Nieves Velez de Mendizabal; Thomas I F H Cremers; Bruce G Pollock; Benoit H Mulsant; Gary Remington; Robert R Bies
Journal:  J Transl Med       Date:  2014-08-20       Impact factor: 5.531

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.